曲妥珠-话题@MedSci

#曲妥珠#

132篇内容 | 2975人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1648129, encodeId=970f1648129e3, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症, objectType=article, longId=146626, objectId=e59d146626ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e59d146626ef, replyNumber=0, likeNumber=70, createdTime=2018-08-29, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e59d146626ef, moduleTitle=Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e59d146626ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648131, encodeId=e94e164813123, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Ann Oncol：HER-2无扩增早期乳腺癌患者，曲妥珠单抗能减少转移复发风险？, objectType=article, longId=149573, objectId=5ecf1495e338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ecf1495e338, replyNumber=0, likeNumber=64, createdTime=2019-02-09, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ecf1495e338, moduleTitle=Ann Oncol：HER-2无扩增早期乳腺癌患者，曲妥珠单抗能减少转移复发风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ecf1495e338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648113, encodeId=93e31648113ff, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, objectType=article, longId=124477, objectId=e6f71244e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f71244e794, replyNumber=0, likeNumber=73, createdTime=2018-01-31, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f71244e794, moduleTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f71244e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648120, encodeId=625a1648120f2, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=CLIN CANCER RES：HER-2阳性转移性胃癌曲妥珠单抗原发耐药的生物学标志, objectType=article, longId=131749, objectId=776a131e495c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=776a131e495c, replyNumber=0, likeNumber=64, createdTime=2018-11-17, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=776a131e495c, moduleTitle=CLIN CANCER RES：HER-2阳性转移性胃癌曲妥珠单抗原发耐药的生物学标志, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=776a131e495c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648125, encodeId=e174164812541, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, objectType=article, longId=136871, objectId=94111368e1b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94111368e1b3, replyNumber=0, likeNumber=75, createdTime=2018-08-09, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94111368e1b3, moduleTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94111368e1b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648115, encodeId=3f2d164811541, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=NSABP B-47证实HER2低表达乳腺癌未从曲妥珠单抗辅助治疗获益, objectType=article, longId=128634, objectId=47f31286349d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47f31286349d, replyNumber=0, likeNumber=70, createdTime=2018-11-05, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47f31286349d, moduleTitle=NSABP B-47证实HER2低表达乳腺癌未从曲妥珠单抗辅助治疗获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47f31286349d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648121, encodeId=63701648121b9, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Int J Cardiol：蒽环类和曲妥珠单抗治疗乳腺癌后心脏效应的晚期特征！, objectType=article, longId=131954, objectId=44c9131954e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44c9131954e8, replyNumber=0, likeNumber=65, createdTime=2018-06-28, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44c9131954e8, moduleTitle=Int J Cardiol：蒽环类和曲妥珠单抗治疗乳腺癌后心脏效应的晚期特征！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44c9131954e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648118, encodeId=665c16481180b, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Her2阳性乳腺癌的靶向治疗--曲妥珠单抗, objectType=article, longId=130228, objectId=82b6130228f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82b6130228f5, replyNumber=0, likeNumber=65, createdTime=2018-10-25, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82b6130228f5, moduleTitle=Her2阳性乳腺癌的靶向治疗--曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82b6130228f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648117, encodeId=5126164811e0d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=J Clin Oncol：拉帕替尼+曲妥珠单抗单抗+AI治疗HR+HER2+转移性乳腺癌, objectType=article, longId=129990, objectId=5260129990bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5260129990bd, replyNumber=0, likeNumber=55, createdTime=2018-06-24, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5260129990bd, moduleTitle=J Clin Oncol：拉帕替尼+曲妥珠单抗单抗+AI治疗HR+HER2+转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5260129990bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648114, encodeId=9023164811470, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, objectType=article, longId=125185, objectId=de17125185b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de17125185b2, replyNumber=0, likeNumber=0, createdTime=2018-06-10, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de17125185b2, moduleTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de17125185b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648108, encodeId=15c11648108f5, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JAMA Oncology：哪种患者可从曲妥珠单抗vs拉帕替尼中获益最多？, objectType=article, longId=107568, objectId=cbe610e56822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe610e56822, replyNumber=0, likeNumber=53, createdTime=2018-05-22, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe610e56822, moduleTitle=JAMA Oncology：哪种患者可从曲妥珠单抗vs拉帕替尼中获益最多？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe610e56822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648107, encodeId=202d164810ed9, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Clin Cancer Res：HER2+早期乳腺癌新辅助曲妥珠单抗后pCR取决于HER2/CEP17比值, objectType=article, longId=106849, objectId=78b6106849a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78b6106849a2, replyNumber=0, likeNumber=63, createdTime=2017-11-25, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78b6106849a2, moduleTitle=Clin Cancer Res：HER2+早期乳腺癌新辅助曲妥珠单抗后pCR取决于HER2/CEP17比值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78b6106849a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648111, encodeId=f861164811143, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。, objectType=article, longId=121373, objectId=6a6c1213e360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a6c1213e360, replyNumber=0, likeNumber=60, createdTime=2018-02-27, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a6c1213e360, moduleTitle=Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a6c1213e360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648123, encodeId=9b221648123f6, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：卡铂-紫杉醇 vs 卡铂-紫杉醇-曲妥珠单抗治疗子宫浆液性癌, objectType=article, longId=133724, objectId=4a7d133e24be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7d133e24be, replyNumber=0, likeNumber=69, createdTime=2019-02-14, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7d133e24be, moduleTitle=JCO：卡铂-紫杉醇 vs 卡铂-紫杉醇-曲妥珠单抗治疗子宫浆液性癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a7d133e24be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648116, encodeId=5abb164811617, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药, objectType=article, longId=128870, objectId=4e4b1288e05f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e4b1288e05f, replyNumber=0, likeNumber=58, createdTime=2018-11-17, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e4b1288e05f, moduleTitle=JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e4b1288e05f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648106, encodeId=a1c416481066d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO: 曲妥珠单抗化疗方案对早期乳腺癌老年妇女的毒性和有效性分析, objectType=article, longId=106441, objectId=da0b10644137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da0b10644137, replyNumber=0, likeNumber=87, createdTime=2018-03-05, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da0b10644137, moduleTitle=JCO: 曲妥珠单抗化疗方案对早期乳腺癌老年妇女的毒性和有效性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da0b10644137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648112, encodeId=03d11648112b6, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=殷咏梅教授：曲妥珠单抗失败后，续用曲妥珠单抗与换用拉帕替尼之争, objectType=article, longId=122491, objectId=b6491224911d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6491224911d, replyNumber=0, likeNumber=71, createdTime=2018-03-18, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6491224911d, moduleTitle=殷咏梅教授：曲妥珠单抗失败后，续用曲妥珠单抗与换用拉帕替尼之争, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6491224911d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648103, encodeId=82c316481036f, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet Oncol：曲妥珠单抗生物类似物：CT-P6即将来临！, objectType=article, longId=101689, objectId=a8fc10168901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8fc10168901, replyNumber=0, likeNumber=87, createdTime=2017-12-12, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8fc10168901, moduleTitle=Lancet Oncol：曲妥珠单抗生物类似物：CT-P6即将来临！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8fc10168901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648110, encodeId=6da8164811075, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=【CSCO 2017】曲妥珠单抗进入医保推动胃癌抗Her2治疗普及——秦叔逵教授解读新医保目录对胃癌治疗影响, objectType=article, longId=115046, objectId=611311504698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=611311504698, replyNumber=0, likeNumber=73, createdTime=2017-11-01, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=611311504698, moduleTitle=【CSCO 2017】曲妥珠单抗进入医保推动胃癌抗Her2治疗普及——秦叔逵教授解读新医保目录对胃癌治疗影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=611311504698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648099, encodeId=424b164809968, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率, objectType=article, longId=93205, objectId=fef993205fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef993205fc, replyNumber=0, likeNumber=71, createdTime=2017-08-13, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef993205fc, moduleTitle=The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef993205fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

曲妥珠

2020-05-29

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症

2018-08-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Ann Oncol：HER-2无扩增早期乳腺癌患者，曲妥珠单抗能减少转移复发风险？

2019-02-09

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌

2018-01-31

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

CLIN CANCER RES：HER-2阳性转移性胃癌曲妥珠单抗原发耐药的生物学标志

2018-11-17

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活

2018-08-09

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

NSABP B-47证实HER2低表达乳腺癌未从曲妥珠单抗辅助治疗获益

2018-11-05

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

Int J Cardiol：蒽环类和曲妥珠单抗治疗乳腺癌后心脏效应的晚期特征！

2018-06-28

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Her2阳性乳腺癌的靶向治疗--曲妥珠单抗

2018-10-25

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

J Clin Oncol：拉帕替尼+曲妥珠单抗单抗+AI治疗HR+HER2+转移性乳腺癌

2018-06-24

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验

2018-06-10

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JAMA Oncology：哪种患者可从曲妥珠单抗vs拉帕替尼中获益最多？

2018-05-22

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Clin Cancer Res：HER2+早期乳腺癌新辅助曲妥珠单抗后pCR取决于HER2/CEP17比值

2017-11-25

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet oncol：多西他赛、卡铂化疗，联合曲妥珠单抗和帕托珠单抗治疗HER2阳性乳腺癌患者的疗效与副反应。

2018-02-27

仁心济世 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：卡铂-紫杉醇 vs 卡铂-紫杉醇-曲妥珠单抗治疗子宫浆液性癌

2019-02-14

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药

2018-11-17

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO: 曲妥珠单抗化疗方案对早期乳腺癌老年妇女的毒性和有效性分析

2018-03-05

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

殷咏梅教授：曲妥珠单抗失败后，续用曲妥珠单抗与换用拉帕替尼之争

2018-03-18

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet Oncol：曲妥珠单抗生物类似物：CT-P6即将来临！

2017-12-12

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

【CSCO 2017】曲妥珠单抗进入医保推动胃癌抗Her2治疗普及——秦叔逵教授解读新医保目录对胃癌治疗影响

2017-11-01

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

The Lancet Oncology：曲妥珠单抗不能提高HER2阳性晚期胃癌患者的生存率

2017-08-13

科室
- - 订阅+
  - 更多科室
工具
服务